Despite the fact that initial clinical trials showed higher objective response rates (ORR) with EGFR TKIs compared to chemotherapy in lung cancer (specifically non-small cell lung cancer, NSCLC), these trials did not establish an advantage in the general population for progression-free survival (PFS) or overall survival (OS), as these trials enrolled lung cancer patients irrespective of EGFR mutation status [4,5,6]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.